Neoadjuvant chemotherapy in locally advanced breast cancer: A preliminary report
| Autor: | E. Büyükünal, Ibtisam Lale Atahan, Dincer Firat, Nazan Günel, Esmen Baltali, Demirali Onat, Zafer Akcali |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1999 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Nausea medicine.medical_treatment Neutropenia 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine medicine polycyclic compounds skin and connective tissue diseases Neoadjuvant therapy Chemotherapy business.industry General Medicine medicine.disease Radiation therapy 030220 oncology & carcinogenesis medicine.symptom business Febrile neutropenia Epirubicin medicine.drug |
| Popis: | Aims and Background A pilot study of neoadjuvant chemotherapy with cyclophosphamide-epirubicin-5-fluorouracil (FEC) was performed on 85 patients with locally advanced breast cancer. Methods and Study Design Patients received four cycles of neoadjuvant chemotherapy followed by surgery, radiotherapy and a treatment with cyclophosphamide-methotrexate-5-fluorouracil for three cycles. Results Major clinical response was obtained in 76 (89%) patients. Complete response was documented in 14 (17%) patients at pathologic examination of surgical specimen. Grade 1-2 nausea and vomiting was the most common (77%) side effect. Grade 2-3 alopecia was 66%. Grade 2-3 neutropenia occurred in 16% of patients. None of the patients developed febrile neutropenia. Sinus tachycardia was observed only in one patient. Three patients had a more than 10% decrease in the left ventricular ejection fraction without any clinical signs. Nine patients had progressive or stable disease and 4 did not undergo surgery or receive radiation therapy; thus 13 were excluded from survival analysis. After a median follow-up of 31 months (range, 15-41), disease-free survival and overall survival were 20 (range, 13-32) and 23 months (range, 17-32). Conclusions The FEC combination is safe and effective for a neoadjuvant setting in locally advanced breast cancer. A longer follow-up is necessary for the end point results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|